This inventor holds 1 USPTO granted patent and 3 published patent applications. Top assignee: Pelemed Co., Ltd.. Active years: 2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2026
Title: Soo Yeon Jang: Inventor of a Kinase-Inhibitor Patent.
Introduction
Soo Yeon Jang is an inventor based in Seoul, South Korea. His patent work includes research into indirubin derivatives designed to inhibit FLT3 and RET kinases. The available information identifies 1 patent associated with him.
Latest Patents
Jang is named on the patent “Indirubin Derivatives Having Heterobicyclic Moieties and the Use Thereof.” The invention concerns novel indirubin derivatives that may inhibit fms-like tyrosine kinase 3 (FLT3) and rearranged during transfection (RET) kinases. The patent describes potential use of these compounds in preventing or treating diseases associated with mutant FLT3 or mutant RET, particularly acute myeloid leukemia.
Career Highlights
Jang is associated with Pelemed Co., Ltd. His patent reflects work on compounds with potential applications in targeted treatment research, including research related to acute myeloid leukemia.
Collaborations
Yong Chul Kim and Woo Chan Kim are identified as Jang’s coworkers. The patent information provided does not specify their individual contributions to the invention.
Conclusion
Soo Yeon Jang’s patent focuses on indirubin derivatives as potential FLT3 and RET kinase inhibitors, highlighting his contribution to research into compounds that may support treatment of related diseases.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile